<span item_type="fundamental" item_id="c3fe647445ae499fab7555aa4d930302" counter_id="ST/US/DRMAW" env="prod"></span><span item_type="announcement" item_id="582799126791848193" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -1.65.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.829 M.</p><p></p><h3>Segment Revenue and Operational Metrics</h3><ul><li><strong>Research and Development Expenses</strong>: Decreased by $1.9 million from $2.4 million for the three months ended September 30, 2024, to $0.5 million for the same period in 2025, primarily due to decreased clinical expenses from the XYNGARI™ STAR-1 acne study.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li><li><strong>Selling, General and Administrative Expenses</strong>: Increased by $0.4 million from $0.8 million for the three months ended September 30, 2024, to $1.3 million for the same period in 2025, mainly due to increased marketing expenses in preparation for the first product launch in mid-2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: $6.4 million for the nine months ended September 30, 2025, compared to $8.2 million for the same period in 2024, reflecting a decrease in net loss and changes in working capital.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $7.9 million for the nine months ended September 30, 2025, primarily from the January 2025 PIPE financing and the March 2025 Inducement financing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to launch its first OTC product, a topical acne kit, in mid-2026, leveraging its Spongilla technology combined with OTC monograph active ingredients like salicylic acid. This strategic shift aims to accelerate commercialization, reduce regulatory burdens, and address broader consumer segments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has placed the initiation of the Phase 2a clinical trial with Revance on hold, while it evaluates the regulatory and commercial opportunities for its Spongilla technology in the topical delivery of botulinum toxin.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li></ul><h3>Priority</h3><ul><li>The strategic pivot to OTC products is prioritized, with a focus on developing and launching multiple products that can be sold directly to consumers, potentially reducing regulatory burdens and expanding market reach.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm"></span></li></ul>

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0